Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Breast Carcinoma
|
2793 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.740 | 0.875 | 8 | 2013 | 2017 | ||||
Carcinoma of lung
|
1204 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.750 | 0.857 | 7 | 2014 | 2018 | ||||
Malignant neoplasm of breast
|
3417 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.740 | 0.800 | 5 | 2013 | 2016 | ||||
Malignant neoplasm of lung
|
1142 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.750 | 0.800 | 5 | 2014 | 2018 | ||||
Malignant Neoplasms
|
1641 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.050 | 1.000 | 5 | 2015 | 2018 | ||||
Primary malignant neoplasm
|
1374 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.050 | 1.000 | 5 | 2015 | 2018 | ||||
Primary malignant neoplasm of lung
|
981 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.050 | 0.800 | 5 | 2014 | 2018 | ||||
ovarian neoplasm
|
757 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.720 | 1.000 | 3 | 2016 | 2018 | ||||
Squamous cell carcinoma
|
257 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.720 | 1.000 | 3 | 2014 | 2018 | ||||
Squamous cell carcinoma of lung
|
283 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.720 | 1.000 | 3 | 2015 | 2019 | ||||
Carcinoma, Ovarian Epithelial
|
327 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.020 | 1.000 | 2 | 2016 | 2018 | ||||
Malignant neoplasm of ovary
|
315 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.020 | 1.000 | 2 | 2016 | 2018 | ||||
Neoplasms
|
1644 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.020 | 1.000 | 2 | 2015 | 2018 | ||||
Prostate carcinoma
|
1168 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.710 | 1.000 | 2 | 2016 | 2016 | ||||
Small cell carcinoma of lung
|
125 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.710 | 1.000 | 2 | 2017 | 2018 | ||||
Adenocarcinoma of large intestine
|
432 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.700 | 1.000 | 1 | 2016 | 2016 | ||||
Adenocarcinoma of lung (disorder)
|
563 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.700 | 1.000 | 1 | 2016 | 2016 | ||||
Adult Glioblastoma
|
98 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.010 | 1 | 2016 | 2016 | |||||
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
80 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||
Breast Cancer, Familial
|
91 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||
Childhood Glioblastoma
|
98 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.010 | 1 | 2016 | 2016 | |||||
COLORECTAL CANCER, SUSCEPTIBILITY TO, 1
|
374 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.700 | 1.000 | 1 | 2016 | 2016 | ||||
COLORECTAL CANCER, SUSCEPTIBILITY TO, 10
|
370 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.700 | 1.000 | 1 | 2016 | 2016 | ||||
COLORECTAL CANCER, SUSCEPTIBILITY TO, 12
|
373 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.700 | 1.000 | 1 | 2016 | 2016 | ||||
COLORECTAL CANCER, SUSCEPTIBILITY TO, 3
|
368 | 0.608 | 0.360 | 13 | 32398489 | stop gained | A/T | snv | 6.6E-03 | 6.0E-03 | 0.700 | 1.000 | 1 | 2016 | 2016 |